

QUARTERLY STATEMENT

OF THE

Athene Annuity and Life Company

TO THE

Insurance Department

OF THE

STATE OF

**FOR THE QUARTER ENDED
SEPTEMBER 30, 2020**

☒ **LIFE AND ACCIDENT AND HEALTH**

☐ **FRATERNAL BENEFIT SOCIETIES**

2020

STATEMENT AS OF SEPTEMBER 30, 2020 OF THE Athene Annuity and Life Company

ASSETS

| | Current Statement Date | | | 4 December 31 Prior Year Net Admitted Assets |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------------------|-------------------------------------------|-------------------------------------------------------|
| | 1 Assets | 2 Nonadmitted Assets | 3 Net Admitted Assets (Cols. 1 - 2) | |
| 1. Bonds | 38,723,164,492 | | 38,723,164,492 | 36,240,868,412 |
| 2. Stocks: | | | | |
| 2.1 Preferred stocks | 195,969,631 | | 195,969,631 | 138,427,963 |
| 2.2 Common stocks | 624,224,361 | | 624,224,361 | 553,757,140 |
| 3. Mortgage loans on real estate: | | | | |
| 3.1 First liens | 7,477,523,067 | | 7,477,523,067 | 8,686,183,107 |
| 3.2 Other than first liens..... | 1,278,106,136 | | 1,278,106,136 | 1,585,847,605 |
| 4. Real estate: | | | | |
| 4.1 Properties occupied by the company (less \$ encumbrances) | | | | |
| 4.2 Properties held for the production of income (less \$ encumbrances) | 9,388,542 | | 9,388,542 | 9,388,542 |
| 4.3 Properties held for sale (less \$ encumbrances) | | | | 57,000 |
| 5. Cash (\$1,265,772,958), cash equivalents (\$) and short-term investments (\$2,194,114,715) | 3,459,887,673 | | 3,459,887,673 | 2,824,240,288 |
| 6. Contract loans (including \$ premium notes) | 152,556,066 | | 152,556,066 | 167,732,270 |
| 7. Derivatives | 761,489,768 | | 761,489,768 | 703,224,810 |
| 8. Other invested assets | 2,705,034,912 | 799,425 | 2,704,235,488 | 2,490,483,018 |
| 9. Receivables for securities | 29,694,668 | | 29,694,668 | 37,507,207 |
| 10. Securities lending reinvested collateral assets | | | | |
| 11. Aggregate write-ins for invested assets | 7,560,000 | | 7,560,000 | 18,044,029 |
| 12. Subtotals, cash and invested assets (Lines 1 to 11) | 55,424,599,316 | 799,425 | 55,423,799,892 | 53,455,761,388 |
| 13. Title plants less \$ charged off (for Title insurers only) | | | | |
| 14. Investment income due and accrued | 442,320,093 | 6,669,235 | 435,650,858 | 436,969,615 |
| 15. Premiums and considerations: | | | | |
| 15.1 Uncollected premiums and agents' balances in the course of collection | 8,933 | | 8,933 | 3,505 |
| 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums) | 6,843,551 | | 6,843,551 | 7,201,100 |
| 15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$) | | | | |
| 16. Reinsurance: | | | | |
| 16.1 Amounts recoverable from reinsurers | 208,543,522 | | 208,543,522 | 194,170,174 |
| 16.2 Funds held by or deposited with reinsured companies | | | | |
| 16.3 Other amounts receivable under reinsurance contracts | 1,398,007,722 | 435,967 | 1,397,571,755 | 957,005,643 |
| 17. Amounts receivable relating to uninsured plans | | | | |
| 18.1 Current federal and foreign income tax recoverable and interest thereon | 66,984,745 | | 66,984,745 | |
| 18.2 Net deferred tax asset | | | | |
| 19. Guaranty funds receivable or on deposit | 609,371 | | 609,371 | 609,371 |
| 20. Electronic data processing equipment and software | | | | |
| 21. Furniture and equipment, including health care delivery assets (\$) | | | | |
| 22. Net adjustment in assets and liabilities due to foreign exchange rates | | | | |
| 23. Receivables from parent, subsidiaries and affiliates | 5,251,032 | | 5,251,032 | 6,988,270 |
| 24. Health care (\$) and other amounts receivable | 38,806,925 | 2,048,730 | 36,758,194 | 49,801,196 |
| 25. Aggregate write-ins for other than invested assets | 415,325,316 | 13,288,033 | 402,037,283 | 387,364,625 |
| 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) | 58,007,300,524 | 23,241,389 | 57,984,059,135 | 55,495,874,888 |
| 27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts | 11,194,812,393 | | 11,194,812,393 | 10,008,987,370 |
| 28. Total (Lines 26 and 27) | 69,202,112,918 | 23,241,389 | 69,178,871,528 | 65,504,862,258 |
| DETAILS OF WRITE-INS | | | | |
| 1101. Derivative Collateral Asset | 7,560,000 | | 7,560,000 | 18,044,029 |
| 1102. | | | | |
| 1103. | | | | |
| 1198. Summary of remaining write-ins for Line 11 from overflow page | | | | |
| 1199. Totals (Lines 1101 through 1103 plus 1198)(Line 11 above) | 7,560,000 | | 7,560,000 | 18,044,029 |
| 2501. Corporate Owned Life Insurance (COLI) | 400,988,250 | | 400,988,250 | 386,568,895 |
| 2502. Miscellaneous Assets | 14,337,065 | 13,288,033 | 1,049,032 | 795,730 |
| 2503. | | | | |
| 2598. Summary of remaining write-ins for Line 25 from overflow page | | | | |
| 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) | 415,325,316 | 13,288,033 | 402,037,283 | 387,364,625 |

STATEMENT AS OF SEPTEMBER 30, 2020 OF THE Athene Annuity and Life Company

LIABILITIES, SURPLUS AND OTHER FUNDS

| | 1 Current Statement Date | 2 December 31 Prior Year |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|
| 1. Aggregate reserve for life contracts \$45,649,170,417 less \$ included in Line 6.3 (including \$36,529,974,558 Modco Reserve) | 45,649,170,417 | 45,144,173,871 |
| 2. Aggregate reserve for accident and health contracts (including \$1,394,804 Modco Reserve) | 3,017,042 | 3,041,637 |
| 3. Liability for deposit-type contracts (including \$775,213,720 Modco Reserve) | 843,621,427 | 376,755,187 |
| 4. Contract claims: | | |
| 4.1 Life | 195,914,407 | 197,115,576 |
| 4.2 Accident and health | 13,363 | 8,577 |
| 5. Policyholders' dividends/refunds to members \$ and coupons \$ due and unpaid | | |
| 6. Provision for policyholders' dividends, refunds to members and coupons payable in following calendar year - estimated amounts: | | |
| 6.1 Policyholders' dividends and refunds to members apportioned for payment (including \$ Modco) | | |
| 6.2 Policyholders' dividends and refunds to members not yet apportioned (including \$ Modco) | | |
| 6.3 Coupons and similar benefits (including \$ Modco) | | |
| 7. Amount provisionally held for deferred dividend policies not included in Line 6 | | |
| 8. Premiums and annuity considerations for life and accident and health contracts received in advance less \$ discount; including \$4,417 accident and health premiums | 4,417 | 5,403 |
| 9. Contract liabilities not included elsewhere: | | |
| 9.1 Surrender values on canceled contracts | | |
| 9.2 Provision for experience rating refunds, including the liability of \$ accident and health experience rating refunds of which \$ is for medical loss ratio rebate per the Public Health Service Act | | |
| 9.3 Other amounts payable on reinsurance, including \$ assumed and \$2,375,654,886 ceded | 2,375,654,886 | 1,859,438,315 |
| 9.4 Interest Maintenance Reserve | 105,812,437 | 119,691,633 |
| 10. Commissions to agents due or accrued-life and annuity contracts \$10,754,387 , accident and health \$ and deposit-type contract funds \$ | 10,754,387 | 10,612,690 |
| 11. Commissions and expense allowances payable on reinsurance assumed | | |
| 12. General expenses due or accrued | 23,458,376 | 16,234,198 |
| 13. Transfers to Separate Accounts due or accrued (net) (including \$(482) accrued for expense allowances recognized in reserves, net of reinsured allowances) | 2,138,908,518 | 1,758,070,283 |
| 14. Taxes, licenses and fees due or accrued, excluding federal income taxes | 631,600 | 631,600 |
| 15.1 Current federal and foreign income taxes, including \$ on realized capital gains (losses) | | 4,859,895 |
| 15.2 Net deferred tax liability | 18,576,082 | 63,803,851 |
| 16. Unearned investment income | 2,347,639 | 3,714,756 |
| 17. Amounts withheld or retained by reporting entity as agent or trustee | 2,364,382 | 1,388,334 |
| 18. Amounts held for agents' account, including \$2,112,238 agents' credit balances | 2,112,238 | 1,077,550 |
| 19. Remittances and items not allocated | 155,495,167 | 68,745,042 |
| 20. Net adjustment in assets and liabilities due to foreign exchange rates | | |
| 21. Liability for benefits for employees and agents if not included above | 77,395 | |
| 22. Borrowed money \$ and interest thereon \$ | | 50,144,194 |
| 23. Dividends to stockholders declared and unpaid | | |
| 24. Miscellaneous liabilities: | | |
| 24.01 Asset valuation reserve | 815,780,435 | 797,698,439 |
| 24.02 Reinsurance in unauthorized and certified (\$) companies | | |
| 24.03 Funds held under reinsurance treaties with unauthorized and certified (\$) reinsurers | 1,334,210,382 | 1,369,159,277 |
| 24.04 Payable to parent, subsidiaries and affiliates | 13,718,086 | 12,960,550 |
| 24.05 Drafts outstanding | | |
| 24.06 Liability for amounts held under uninsured plans | | |
| 24.07 Funds held under coinsurance | | |
| 24.08 Derivatives | 76,035,419 | 41,536,552 |
| 24.09 Payable for securities | 140,397,484 | 15,439,662 |
| 24.10 Payable for securities lending | | |
| 24.11 Capital notes \$ and interest thereon \$ | | |
| 25. Aggregate write-ins for liabilities | 3,230,011,443 | 2,744,276,394 |
| 26. Total liabilities excluding Separate Accounts business (Lines 1 to 25) | 57,138,087,430 | 54,660,583,465 |
| 27. From Separate Accounts Statement | 10,736,496,057 | 9,635,631,049 |
| 28. Total liabilities (Lines 26 and 27) | 67,874,583,487 | 64,296,214,514 |
| 29. Common capital stock | 10,000,000 | 10,000,000 |
| 30. Preferred capital stock | | |
| 31. Aggregate write-ins for other than special surplus funds | | |
| 32. Surplus notes | | |
| 33. Gross paid in and contributed surplus | 968,675,253 | 961,950,467 |
| 34. Aggregate write-ins for special surplus funds | | |
| 35. Unassigned funds (surplus) | 325,612,789 | 236,697,277 |
| 36. Less treasury stock, at cost: | | |
| 36.1 shares common (value included in Line 29 \$) | | |
| 36.2 shares preferred (value included in Line 30 \$) | | |
| 37. Surplus (Total Lines 31+32+33+34+35-36) (including \$458,316,336 in Separate Accounts Statement) | 1,294,288,042 | 1,198,647,744 |
| 38. Totals of Lines 29, 30 and 37 | 1,304,288,042 | 1,208,647,744 |
| 39. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3) | 69,178,871,528 | 65,504,862,258 |
| DETAILS OF WRITE-INS | | |
| 2501. Derivative and Other Collateral Liability | 2,148,096,668 | 2,361,611,119 |
| 2502. Repurchase Agreement Liability | 911,431,554 | 210,878,335 |
| 2503. Amount Due Reinsurer | 74,312,755 | 60,703,555 |
| 2598. Summary of remaining write-ins for Line 25 from overflow page | 96,170,467 | 111,083,386 |
| 2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) | 3,230,011,443 | 2,744,276,394 |
| 3101. | | |
| 3102. | | |
| 3103. | | |
| 3198. Summary of remaining write-ins for Line 31 from overflow page | | |
| 3199. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above) | | |
| 3401. | | |
| 3402. | | |
| 3403. | | |
| 3498. Summary of remaining write-ins for Line 34 from overflow page | | |
| 3499. Totals (Lines 3401 through 3403 plus 3498)(Line 34 above) | | |

STATEMENT AS OF SEPTEMBER 30, 2020 OF THE Athene Annuity and Life Company

SUMMARY OF OPERATIONS

| | 1 | 2 | 3 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------|---------------------------------|
| | Current Year To Date | Prior Year To Date | Prior Year Ended December 31 |
| 1. Premiums and annuity considerations for life and accident and health contracts | 813,555,891 | 1,580,038,289 | 1,696,380,582 |
| 2. Considerations for supplementary contracts with life contingencies | 5,823,307 | 1,926,663 | 3,426,266 |
| 3. Net investment income | 1,840,422,105 | 1,901,788,404 | 2,591,326,621 |
| 4. Amortization of Interest Maintenance Reserve (IMR) | 4,166,286 | 8,676,159 | 12,514,845 |
| 5. Separate Accounts net gain from operations excluding unrealized gains or losses | 369,476 | 28,332,055 | 32,768,190 |
| 6. Commissions and expense allowances on reinsurance ceded | 547,758,592 | 636,876,980 | 837,341,226 |
| 7. Reserve adjustments on reinsurance ceded | (988,424,642) | (1,256,709,258) | (1,862,540,764) |
| 8. Miscellaneous Income: | | | |
| 8.1 Income from fees associated with investment management, administration and contract guarantees from Separate Accounts | 5,627,659 | 4,242,771 | 6,000,486 |
| 8.2 Charges and fees for deposit-type contracts | | | |
| 8.3 Aggregate write-ins for miscellaneous income | 17,692,621 | 22,075,394 | 30,367,195 |
| 9. Totals (Lines 1 to 8.3) | 2,246,991,295 | 2,927,247,456 | 3,347,584,647 |
| 10. Death benefits | 1,507,322 | 754,762 | 986,802 |
| 11. Matured endowments (excluding guaranteed annual pure endowments) | 14,642 | | |
| 12. Annuity benefits | 260,687,698 | 214,075,590 | 287,631,322 |
| 13. Disability benefits and benefits under accident and health contracts | 296,319 | 347,545 | 442,263 |
| 14. Coupons, guaranteed annual pure endowments and similar benefits | | | |
| 15. Surrender benefits and withdrawals for life contracts | 521,932,631 | 584,150,333 | 766,344,853 |
| 16. Group conversions | | | |
| 17. Interest and adjustments on contract or deposit-type contract funds | 4,791,790 | 11,185,657 | 16,093,107 |
| 18. Payments on supplementary contracts with life contingencies | 6,156,416 | 6,964,782 | 9,086,679 |
| 19. Increase in aggregate reserves for life and accident and health contracts | 504,971,951 | 296,860,991 | 190,160,379 |
| 20. Totals (Lines 10 to 19) | 1,300,358,770 | 1,114,339,659 | 1,270,745,405 |
| 21. Commissions on premiums, annuity considerations, and deposit-type contract funds (direct business only) | 375,975,908 | 477,185,501 | 584,113,567 |
| 22. Commissions and expense allowances on reinsurance assumed | 906,319 | 341,684 | 556,982 |
| 23. General insurance expenses and fraternal expenses | 244,559,086 | 228,343,434 | 304,788,383 |
| 24. Insurance taxes, licenses and fees, excluding federal income taxes | 11,578,924 | 11,414,304 | 14,348,037 |
| 25. Increase in loading on deferred and uncollected premiums | 1 | (3) | (4) |
| 26. Net transfers to or (from) Separate Accounts net of reinsurance | 152,572,940 | 923,243,240 | 890,959,573 |
| 27. Aggregate write-ins for deductions | 75,342,680 | 91,938,246 | 119,001,844 |
| 28. Totals (Lines 20 to 27) | 2,161,294,628 | 2,846,806,065 | 3,184,513,786 |
| 29. Net gain from operations before dividends to policyholders and federal income taxes (Line 9 minus Line 28) | 85,696,667 | 80,441,391 | 163,070,860 |
| 30. Dividends to policyholders and refunds to members | 25,169 | 38 | 38 |
| 31. Net gain from operations after dividends to policyholders, refunds to members and before federal income taxes (Line 29 minus Line 30) | 85,671,498 | 80,441,353 | 163,070,823 |
| 32. Federal and foreign income taxes incurred (excluding tax on capital gains) | 61,991,915 | (85,630,486) | (108,031,238) |
| 33. Net gain from operations after dividends to policyholders, refunds to members and federal income taxes and before realized capital gains or (losses) (Line 31 minus Line 32) | 23,679,583 | 166,071,839 | 271,102,061 |
| 34. Net realized capital gains (losses) (excluding gains (losses) transferred to the IMR) less capital gains tax of \$(11,601,792) (excluding taxes of \$(3,451,441) transferred to the IMR) | (14,827,972) | (4,118,290) | (30,120,346) |
| 35. Net income (Line 33 plus Line 34) | 8,851,611 | 161,953,550 | 240,981,714 |
| CAPITAL AND SURPLUS ACCOUNT | | | |
| 36. Capital and surplus, December 31, prior year | 1,208,647,744 | 1,234,163,823 | 1,234,163,823 |
| 37. Net income (Line 35) | 8,851,611 | 161,953,550 | 240,981,714 |
| 38. Change in net unrealized capital gains (losses) less capital gains tax of \$(14,865,233)(34,782,022) | (34,782,022) | 73,949,997 | 80,991,683 |
| 39. Change in net unrealized foreign exchange capital gain (loss) | 38,097,607 | (1,857,561) | (11,982,342) |
| 40. Change in net deferred income tax | 30,362,536 | (74,533,920) | (70,731,557) |
| 41. Change in nonadmitted assets | (13,380,869) | 943,827 | (3,100,724) |
| 42. Change in liability for reinsurance in unauthorized and certified companies | | | |
| 43. Change in reserve on account of change in valuation basis, (increase) or decrease | | | |
| 44. Change in asset valuation reserve | (18,081,996) | (65,553,844) | (153,164,616) |
| 45. Change in treasury stock | | | |
| 46. Surplus (contributed to) withdrawn from Separate Accounts during period | (90,000,000) | (20,000,000) | (20,000,000) |
| 47. Other changes in surplus in Separate Accounts Statement | 84,590,539 | 18,491,419 | 21,092,413 |
| 48. Change in surplus notes | | | |
| 49. Cumulative effect of changes in accounting principles | | | |
| 50. Capital changes: | | | |
| 50.1 Paid in | | | |
| 50.2 Transferred from surplus (Stock Dividend) | | | |
| 50.3 Transferred to surplus | | | |
| 51. Surplus adjustment: | | | |
| 51.1 Paid in | 6,724,786 | 7,803,928 | 9,898,224 |
| 51.2 Transferred to capital (Stock Dividend) | | | |
| 51.3 Transferred from capital | | | |
| 51.4 Change in surplus as a result of reinsurance | 78,497,911 | (56,196,300) | (117,123,107) |
| 52. Dividends to stockholders | | (409,420) | (409,420) |
| 53. Aggregate write-ins for gains and losses in surplus | 4,760,193 | (2,207,313) | (1,968,348) |
| 54. Net change in capital and surplus for the year (Lines 37 through 53) | 95,640,297 | 42,384,364 | (25,516,079) |
| 55. Capital and surplus, as of statement date (Lines 36 + 54) | 1,304,288,042 | 1,276,548,187 | 1,208,647,744 |
| DETAILS OF WRITE-INS | | | |
| 08.301. COLI Income | 18,003,335 | 22,062,403 | 30,339,559 |
| 08.302. Miscellaneous (Expense) Income | (310,714) | 12,991 | 27,636 |
| 08.303. | | | |
| 08.398. Summary of remaining write-ins for Line 8.3 from overflow page | | | |
| 08.399. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) | 17,692,621 | 22,075,394 | 30,367,195 |
| 2701. Funds Withheld Adjustment - Ceded | 71,755,443 | 82,538,695 | 115,152,450 |
| 2702. Transfer to IMR - Ceded | 17,626,472 | (31,177,102) | (40,728,435) |
| 2703. Transfer to IMR - MVA Benefits | (14,355,391) | 392,695 | (685,304) |
| 2798. Summary of remaining write-ins for Line 27 from overflow page | 316,155 | 40,183,959 | 45,263,133 |
| 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) | 75,342,680 | 91,938,246 | 119,001,844 |
| 5301. Correction of Prior Period Error | 4,289,474 | (3,161,394) | (3,161,394) |
| 5302. Athene Re IV Tax Sharing Agreement | 470,719 | 954,081 | 1,193,046 |
| 5303. | | | |
| 5398. Summary of remaining write-ins for Line 53 from overflow page | | | |
| 5399. Totals (Lines 5301 through 5303 plus 5398)(Line 53 above) | 4,760,193 | (2,207,313) | (1,968,348) |

STATEMENT AS OF SEPTEMBER 30, 2020 OF THE Athene Annuity and Life Company

CASH FLOW

| | 1 Current Year To Date | 2 Prior Year To Date | 3 Prior Year Ended December 31 |
|-----------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------|--------------------------------------|
| Cash from Operations | | | |
| 1. Premiums collected net of reinsurance | 819,750,284 | 1,582,547,670 | 1,700,658,788 |
| 2. Net investment income | 1,789,073,378 | 1,871,520,493 | 2,558,386,398 |
| 3. Miscellaneous income | 568,980,446 | 662,024,268 | 832,032,297 |
| 4. Total (Lines 1 to 3) | 3,177,804,107 | 4,116,092,430 | 5,091,077,483 |
| 5. Benefit and loss related payments | 1,575,954,608 | 1,816,327,742 | 2,671,322,496 |
| 6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts | (228,265,295) | 625,391,837 | 183,001,819 |
| 7. Commissions, expenses paid and aggregate write-ins for deductions | 619,611,697 | 741,669,841 | 938,772,628 |
| 8. Dividends paid to policyholders | 25,168 | 38 | 38 |
| 9. Federal and foreign income taxes paid (recovered) net of \$ (13,627,031) tax on capital gains (losses) | 119,498,349 | (34,951,935) | (25,243,057) |
| 10. Total (Lines 5 through 9) | 2,086,824,528 | 3,148,437,522 | 3,767,853,924 |
| 11. Net cash from operations (Line 4 minus Line 10) | 1,090,979,580 | 967,654,908 | 1,323,223,559 |
| Cash from Investments | | | |
| 12. Proceeds from investments sold, matured or repaid: | | | |
| 12.1 Bonds | 4,639,741,412 | 4,589,908,313 | 7,753,211,809 |
| 12.2 Stocks | 18,415,994 | 19,432,000 | 45,305,333 |
| 12.3 Mortgage loans | 2,864,889,523 | 719,625,229 | 1,147,107,404 |
| 12.4 Real estate | 4,866 | | |
| 12.5 Other invested assets | 240,642,018 | 176,818,410 | 237,462,497 |
| 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments | (4,133,356) | (410,179) | 772,916 |
| 12.7 Miscellaneous proceeds | 145,115,104 | 145,981,041 | 59,965,719 |
| 12.8 Total investment proceeds (Lines 12.1 to 12.7) | 7,904,675,561 | 5,651,354,815 | 9,243,825,678 |
| 13. Cost of investments acquired (long-term only): | | | |
| 13.1 Bonds | 7,211,047,483 | 3,297,990,958 | 6,147,696,337 |
| 13.2 Stocks | 110,698,588 | 12,000,000 | 229,269,546 |
| 13.3 Mortgage loans | 1,585,235,155 | 2,791,863,797 | 3,716,569,675 |
| 13.4 Real estate | | | |
| 13.5 Other invested assets | 281,270,637 | 447,201,142 | 671,956,800 |
| 13.6 Miscellaneous applications | 47,576,681 | | 5,892,729 |
| 13.7 Total investments acquired (Lines 13.1 to 13.6) | 9,235,828,544 | 6,549,055,897 | 10,771,385,087 |
| 14. Net increase (or decrease) in contract loans and premium notes | (15,176,204) | (14,708,805) | (21,776,640) |
| 15. Net cash from investments (Line 12.8 minus Line 13.7 and Line 14) | (1,315,976,779) | (882,992,277) | (1,505,782,769) |
| Cash from Financing and Miscellaneous Sources | | | |
| 16. Cash provided (applied): | | | |
| 16.1 Surplus notes, capital notes | | | |
| 16.2 Capital and paid in surplus, less treasury stock | | | |
| 16.3 Borrowed funds | (50,144,194) | | 50,144,194 |
| 16.4 Net deposits on deposit-type contracts and other insurance liabilities | 466,866,240 | (49,260,796) | (58,842,745) |
| 16.5 Dividends to stockholders | | | |
| 16.6 Other cash provided (applied) | 443,922,539 | 1,043,632,077 | 1,571,245,152 |
| 17. Net cash from financing and miscellaneous sources (Line 16.1 through Line 16.4 minus Line 16.5 plus Line 16.6) | 860,644,585 | 994,371,281 | 1,562,546,601 |
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS | | | |
| 18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) | 635,647,385 | 1,079,033,912 | 1,379,987,391 |
| 19. Cash, cash equivalents and short-term investments: | | | |
| 19.1 Beginning of year | 2,824,240,288 | 1,444,252,897 | 1,444,252,897 |
| 19.2 End of period (Line 18 plus Line 19.1) | 3,459,887,673 | 2,523,286,808 | 2,824,240,288 |

Note: Supplemental disclosures of cash flow information for non-cash transactions:

| | | | |
|--------------------------------------------------------------------------------------------------------|-----------------|---------------|-----------------|
| 20.0001. Capital contribution of stock compensation expense (financing) | 6,724,786 | 7,803,928 | 9,898,224 |
| 20.0002. Capital contribution of stock compensation expense (investing) | (365,967) | (605,431) | (765,250) |
| 20.0003. Capital contribution of stock compensation expense (operating) | (6,358,819) | (7,198,497) | (9,132,974) |
| 20.0004. Security exchanges and asset in kind trades – bond proceeds (investing) | 1,605,507,746 | 615,570,775 | 1,409,147,543 |
| 20.0005. Security exchanges and asset in kind trades – bonds acquired (investing) | (1,605,507,746) | (615,570,775) | (1,552,615,543) |
| 20.0006. Security exchanges and asset in kind trades – other invested asset proceeds (investing) | 374,297,159 | 8,779,919 | 11,532,999 |
| 20.0007. Security exchanges and asset in kind trades – other invested asset acquired (investing) | (374,297,159) | (8,779,919) | (11,532,999) |
| 20.0008. Transfer from Schedule B to Schedule BA – proceeds (investing) | 218,610,865 | 1,258,032 | 1,688,704 |
| 20.0009. Transfer from Schedule B to Schedule BA – acquired (investing) | (218,610,865) | (1,258,032) | (1,688,704) |
| 20.0010. Reinsurance activity settled in bonds (operating) | 137,774,149 | 196,491,718 | 345,189,964 |

STATEMENT AS OF SEPTEMBER 30, 2020 OF THE Athene Annuity and Life Company

Note: Supplemental disclosures of cash flow information for non-cash transactions:

| | | | |
|------------------------------------------------------------------------------------------|---------------|---------------|---------------|
| 20.0011. Reinsurance activity settled in bonds (investing) | (137,774,149) | (196,491,718) | (345,189,964) |
| 20.0012. Interest capitalization (operating) | 5,402,905 | 3,967,809 | 4,503,249 |
| 20.0013. Interest capitalization (investing) | (5,402,905) | (3,967,809) | (4,503,249) |
| 20.0014. Security exchanges and asset in kind trades – stock proceeds (investing) | 1,714,400 | | 190,000,331 |
| 20.0015. Security exchanges and asset in kind trades – stocks acquired (investing) | (1,714,400) | | (46,532,331) |
| 20.0016. Dividends paid – Schedule BA distribution (investing) | | 409,420 | 409,420 |
| 20.0017. Dividends paid (financing) | | (409,420) | (409,420) |

Notes to the Financial Statements

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of **Athene Annuity and Life Company** (the Company) have been prepared in conformity with the accounting practices prescribed or permitted by the National Association of Insurance Commissioners (NAIC) and the State of Iowa.

The Insurance Division, Department of Commerce, of the State of Iowa (the Division) recognizes only statutory accounting practices prescribed or permitted by the State of Iowa for determining and reporting the financial condition and results of operations of an insurance company and for determining its solvency under the Iowa Insurance Law. The NAIC’s *Accounting Practices & Procedures Manual* (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Iowa. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices.

Among the products issued by the Company are indexed universal life insurance and indexed annuities. These products allow a portion of the premium to earn interest based on certain indices, such as the Standard & Poor’s 500 Composite Stock Price Index. Call options, futures, variance swaps and total return swaps are purchased to hedge the growth in interest credited to the customer as a direct result of increases in the related indices. In 2006, the Commissioner of the Division issued Bulletin 06-01, *Accounting for Derivative Instruments Used to Hedge the Growth in Interest Credited for Index Products*, which prescribes that an insurer may elect to recognize changes in the fair value of derivative instruments purchased to hedge indexed products in the statement of operations. The Company has elected to apply Bulletin 06-01 to its futures, variance swaps and total return swaps, which resulted in an increase of \$1.6 million and \$2.2 million to the Company’s net income for the nine months ended September 30, 2020 and for the year ended December 31, 2019, respectively. Application of Bulletin 06-01 does not impact the Company’s statutory surplus amounts.

In 2009, the Commissioner of the Division promulgated Iowa Administrative Code (IAC) Section 191-97, *Accounting for Certain Derivative Instruments Used to Hedge the Growth in Interest Credited for Indexed Insurance Products and Accounting for the Indexed Insurance Products Reserve*, which prescribes that an insurer may elect (i) to use an amortized cost method to account for certain derivative instruments, such as call options, purchased to hedge the growth in interest credited to the customer on indexed insurance products and (ii) to utilize an indexed annuity reserve calculation methodology under which call options associated with the current index interest crediting term are valued at zero. IAC Section 191-97 does not apply to products that do not guarantee a minimum interest accumulation, such as our variable and index-linked deferred annuities. The Company has elected to apply IAC Section 191-97 to its eligible over the counter (OTC) call options and reserve liabilities. As a result, the Company’s net income decreased by \$42.1 million and increased by \$113.6 million for the nine months ended September 30, 2020 and for the year ended December 31, 2019, respectively, and the Company’s statutory surplus decreased by \$44.3 million and \$79.8 million as of September 30, 2020 and December 31, 2019, respectively.

The NAIC requires annuities issued by life insurance companies on or after January 1, 2015, to use the 2012 Individual Annuity Reserving (IAR) Mortality Table. In 2015, the Division promulgated IAC Section 43.3(5), which set an elective alternative effective date of January 1, 2016 for adoption of the 2012 IAR Mortality Table. The Company chose to use the Annuity 2000 Mortality Table for all annuities issued in 2015, which resulted in an increase of \$0.3 million and \$1.6 million to the Company’s net income for the nine months ended September 30, 2020 and for the year ended December 31, 2019, respectively. The Company’s statutory surplus increased by \$5.3 million and \$4.9 million as of September 30, 2020 and December 31, 2019, respectively.

A reconciliation of the Company’s net income and statutory surplus between practices prescribed or permitted by the State of Iowa and NAIC SAP is shown below:

| | SSAP # | F/S Page | F/S Line # | 09/30/2020 | 12/31/2019 |
|---------------------------------------------------------------------------------|--------|----------|------------|------------------|------------------|
| Net Income | | | | | |
| (1) State basis (Page 4, Line 35, Columns 1 & 3) | XXX | XXX | XXX | \$ 8,851,611 | \$ 240,981,714 |
| (2) State prescribed practices that are an increase / (decrease) from NAIC SAP: | | | | | |
| Derivative Instruments Bulletin 06-01 | 86 | 4 | 38 | 1,625,920 | 2,192,043 |
| Derivative Instruments and Equity Indexed Reserves IAC 191-97 | 86, 51 | 2, 3 | 7, 1 | (42,077,484) | 113,621,392 |
| 2012 IAR Mortality Table for Annuities Issued in 2015 IAC 43.3(5) | 51 | 3 | 1 | 333,585 | 1,648,673 |
| (3) State permitted practices that are an increase / (decrease) from NAIC SAP: | | | | | |
| (4) NAIC SAP (1-2-3=4) | XXX | XXX | XXX | \$ 48,969,590 | \$ 123,519,605 |
| Surplus | | | | | |
| (5) State basis (Page 3, Line 38, Columns 1 & 2) | XXX | XXX | XXX | \$ 1,304,288,042 | \$ 1,208,647,744 |
| (6) State prescribed practices that are an increase / (decrease) from NAIC SAP: | | | | | |
| Derivative Instruments and Equity Indexed Reserves IAC 191-97 | 86, 51 | 2, 3 | 7, 1 | (44,324,069) | (79,827,185) |
| 2012 IAR Mortality Table for Annuities Issued 2005 IAC 43.3(5) | 51 | 3 | 1 | 5,261,797 | 4,928,212 |
| (7) State permitted practices that are an increase / (decrease) from NAIC SAP: | | | | | |
| (8) NAIC SAP (5-6-7=8) | XXX | XXX | XXX | \$ 1,343,350,314 | \$ 1,283,546,716 |

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC SAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the period. Our estimates may vary as more information about the extent to which the Coronavirus Disease of 2019 and the resulting impact on economic conditions and the financial markets become known. Actual results may differ from the estimates used in preparing the financial statements.

C. Accounting Policy

- (1) Short-term investments - No Significant Changes
- (2) Bonds, other than loan-backed and structured securities, are stated at amortized cost or fair value based on their rating by the NAIC. Bonds held at amortized cost are amortized using the scientific interest method on a yield-to-worst basis.

Notes to the Financial Statements

1. Summary of Significant Accounting Policies and Going Concern (Continued)

- (3) Common stocks - No Significant Changes
- (4) Preferred stocks - No Significant Changes
- (5) Mortgage loans - No Significant Changes
- (6) Loan-backed and structured securities are stated at amortized cost or fair market value based on their rating by the NAIC. Changes to estimated cash flows on the securities are accounted for retrospectively for securities that are highly rated at the time of purchase and in which the security cannot be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. The prospective method is used for those securities where an other than temporary impairment has been taken, the security is not highly rated at the time of purchase, securities where receipt of all contractual principal cash flows is not expected, or those securities that can be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. Loan-backed and structured securities stated at amortized cost are amortized or accreted using the scientific interest method.
- (7) Investments in subsidiaries, controlled and affiliated entities - No Significant Changes
- (8) Investments in joint ventures, partnerships and limited liability entities - No Significant Changes
- (9) Derivatives - No Significant Changes
- (10) Investment income as a factor in the premium deficiency calculation - No Significant Changes
- (11) Liabilities for losses and loss/claim adjustment expenses - No Significant Changes
- (12) Changes in capitalization policy - No Significant Changes
- (13) Pharmaceutical rebate receivables - No Significant Changes

D. Going Concern

Management’s assessment of the relevant conditions through November 12, 2020 does not give rise to substantial doubt of the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

During the current year's financial statement preparation, the Company discovered errors within prior period Annual Statements relating to net investment income. After consideration of materiality and in accordance with SSAP No. 3, *Accounting Changes and Correction of Errors*, the corrections were recorded directly to surplus. The net impact of the correction of net investment income increased surplus by \$4.3 million in 2020 and represented less than 1% of ending capital and surplus as of September 30, 2020 and December 31, 2019.

3. Business Combinations and Goodwill - No Significant Changes

4. Discontinued Operations - None

5. Investments

- A. Mortgage Loans, including Mezzanine Real Estate Loans - No Significant Changes
- B. Debt Restructuring - No Significant Changes
- C. Reverse Mortgages - None
- D. Loan-Backed Securities
 - (1) Prepayment assumptions for loan-backed bonds and structured securities were obtained from broker dealer survey values or internal estimates.
 - (2) Loan-backed and structured securities with a recognized other-than-temporary impairment (OTTI)

No other-than-temporary impairment was recognized on loan-backed securities due to the intent to sell or inability or lack of intent to retain the investment for a period of time sufficient to recover the amortized cost basis.
 - (3) Securities held that were other-than-temporarily impaired due to the present value of cash flows expected to be collected was less than the amortized cost of securities

| (1) | (2) | (3) | (4) | (5) | (6) | (7) |
|--------------|---------------------------------------------------------------------------------|---------------------------------------------|-----------------|------------------------------|-------------------------------|--------------------------------------------------|
| CUSIP | Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI | Present Value of Projected Cash Flows | Recognized OTTI | Amortized Cost After OTTI | Fair Value at Time of OTTI | Date of Financial Statement Where Reported |
| ..07386HQQW4 | \$ 5,614,740 | \$ 5,531,190 | \$ 83,550 | \$ 5,531,190 | \$ 5,430,675 | 03/31/2020 |
| ..12544DAL3 | 1,574,952 | 1,506,494 | 68,458 | 1,506,494 | 1,290,144 | 03/31/2020 |
| ..12668BTG8 | 784,722 | 749,703 | 35,019 | 749,703 | 600,827 | 03/31/2020 |
| ..45660N5H4 | 1,119,923 | 1,081,573 | 38,350 | 1,081,573 | 941,222 | 03/31/2020 |
| ..86359LHX0 | 4,871,795 | 4,425,174 | 446,621 | 4,425,174 | 4,073,744 | 03/31/2020 |
| ..7036PG5 | 1,404,107 | 1,297,502 | 106,605 | 1,297,502 | 1,297,502 | 06/30/2020 |
| ..05963SAE2 | 3,477,845 | 3,186,568 | 291,277 | 3,186,568 | 3,123,698 | 06/30/2020 |
| ..73871BN4 | 917,551 | 821,825 | 95,727 | 821,825 | 821,825 | 06/30/2020 |
| ..05532KAB7 | 2,101,500 | 2,064,550 | 36,950 | 2,064,550 | 2,064,550 | 06/30/2020 |
| ..05535VBB9 | 4,298,143 | 4,255,141 | 43,002 | 4,255,141 | 4,140,200 | 06/30/2020 |
| ..05541YBJ8 | 5,360,552 | 5,222,649 | 137,904 | 5,222,649 | 5,183,063 | 06/30/2020 |
| ..05539DBZ2 | 1,203,705 | 1,151,275 | 52,430 | 1,151,275 | 1,151,275 | 06/30/2020 |
| ..05529DAA0 | 4,918,572 | 4,611,194 | 307,378 | 4,611,194 | 4,611,194 | 06/30/2020 |
| ..05529DAA0 | 3,513,236 | 3,293,683 | 219,554 | 3,293,683 | 3,293,683 | 06/30/2020 |

Notes to the Financial Statements

5. Investments (Continued)

| (1) | (2) | (3) | (4) | (5) | (6) | (7) |
|-----------|---------------------------------------------------------------------------------|---------------------------------------------|-----------------|------------------------------|-------------------------------|--------------------------------------------------|
| CUSIP | Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI | Present Value of Projected Cash Flows | Recognized OTTI | Amortized Cost After OTTI | Fair Value at Time of OTTI | Date of Financial Statement Where Reported |
| 16165LAF7 | 26,498,636 | 26,413,755 | 84,881 | 26,413,755 | 26,413,755 | 06/30/2020 |
| 16163CAH5 | 1,104,371 | 1,075,564 | 28,807 | 1,075,564 | 1,069,165 | 06/30/2020 |
| 17322JAD5 | 11,626,825 | 11,528,339 | 98,486 | 11,528,339 | 11,299,737 | 06/30/2020 |
| 225470EC3 | 2,117,986 | 1,945,148 | 172,839 | 1,945,148 | 1,945,148 | 06/30/2020 |
| 12641TCC8 | 5,865,912 | 5,602,267 | 263,645 | 5,602,267 | 5,518,223 | 06/30/2020 |
| 12667G3L5 | 2,181,079 | 2,080,657 | 100,422 | 2,080,657 | 2,080,657 | 06/30/2020 |
| 12668AFW0 | 1,444,719 | 1,320,815 | 123,904 | 1,320,815 | 1,320,815 | 06/30/2020 |
| 12668AUV5 | 472,455 | 413,597 | 58,857 | 413,597 | 413,597 | 06/30/2020 |
| 12668AZX6 | 2,805,889 | 2,698,555 | 107,333 | 2,698,555 | 2,698,555 | 06/30/2020 |
| 12668A5X9 | 4,238,231 | 4,080,780 | 157,451 | 4,080,780 | 4,080,780 | 06/30/2020 |
| 12667F5W1 | 3,623,195 | 3,467,461 | 155,734 | 3,467,461 | 3,467,461 | 06/30/2020 |
| 12667GH89 | 694,587 | 668,037 | 26,550 | 668,037 | 668,037 | 06/30/2020 |
| 12668BTG8 | 687,949 | 577,995 | 109,954 | 577,995 | 577,995 | 06/30/2020 |
| 12669FW82 | 1,293,805 | 1,238,182 | 55,623 | 1,238,182 | 1,238,182 | 06/30/2020 |
| 12669GSN2 | 4,708,635 | 4,596,631 | 112,004 | 4,596,631 | 4,596,631 | 06/30/2020 |
| 126670JY5 | 1,725,471 | 1,698,895 | 26,576 | 1,698,895 | 1,665,344 | 06/30/2020 |
| 12669GN64 | 3,590,110 | 3,532,864 | 57,247 | 3,532,864 | 3,532,864 | 06/30/2020 |
| 12544DAL3 | 1,401,803 | 1,138,612 | 263,191 | 1,138,612 | 1,138,612 | 06/30/2020 |
| 251510FB4 | 1,280,794 | 1,226,217 | 54,578 | 1,226,217 | 1,226,217 | 06/30/2020 |
| 23332UGM0 | 11,584,182 | 11,114,907 | 469,274 | 11,114,907 | 11,114,907 | 06/30/2020 |
| 32051G2V6 | 2,360,994 | 2,190,714 | 170,280 | 2,190,714 | 2,190,714 | 06/30/2020 |
| 32051HAD5 | 1,187,019 | 1,062,223 | 124,796 | 1,062,223 | 1,062,223 | 06/30/2020 |
| 39538RAA7 | 9,861,538 | 9,306,499 | 555,040 | 9,306,499 | 9,306,499 | 06/30/2020 |
| 36242DXG3 | 4,469,875 | 4,220,893 | 248,982 | 4,220,893 | 4,220,893 | 06/30/2020 |
| 36242DXG3 | 13,960,842 | 12,871,171 | 1,089,671 | 12,871,171 | 12,871,171 | 06/30/2020 |
| 36242DT52 | 2,161,824 | 2,132,754 | 29,070 | 2,132,754 | 2,132,754 | 06/30/2020 |
| 41161PVJ9 | 5,045,420 | 4,887,392 | 158,028 | 4,887,392 | 4,887,392 | 06/30/2020 |
| 41161PVK6 | 3,827,826 | 3,683,501 | 144,325 | 3,683,501 | 3,683,501 | 06/30/2020 |
| 41161PA52 | 6,248,049 | 4,965,408 | 1,282,641 | 4,965,408 | 4,965,408 | 06/30/2020 |
| 41161PLQ4 | 2,538,887 | 2,308,191 | 230,696 | 2,308,191 | 2,308,191 | 06/30/2020 |
| 41161PMF7 | 17,660,748 | 16,612,144 | 1,048,604 | 16,612,144 | 16,612,144 | 06/30/2020 |
| 41161MAC4 | 5,037,822 | 4,782,248 | 255,574 | 4,782,248 | 4,782,248 | 06/30/2020 |
| 41161UAC6 | 925,072 | 890,833 | 34,239 | 890,833 | 890,833 | 06/30/2020 |
| 41161XAC0 | 11,281,550 | 11,213,551 | 67,999 | 11,213,551 | 11,213,551 | 06/30/2020 |
| 45660N5H4 | 1,078,135 | 980,541 | 97,594 | 980,541 | 980,541 | 06/30/2020 |
| 45660NS22 | 532,692 | 491,891 | 40,801 | 491,891 | 491,891 | 06/30/2020 |
| 45660NT96 | 3,291,136 | 3,170,465 | 120,671 | 3,170,465 | 3,170,465 | 06/30/2020 |
| 45660LRU5 | 5,624,235 | 5,359,400 | 264,835 | 5,359,400 | 5,359,400 | 06/30/2020 |
| 45660LRU5 | 3,762,149 | 3,556,337 | 205,811 | 3,556,337 | 3,556,337 | 06/30/2020 |
| 45660LWD7 | 12,707,867 | 12,244,404 | 463,464 | 12,244,404 | 12,244,404 | 06/30/2020 |
| 46635AAH6 | 2,868,453 | 2,812,828 | 55,625 | 2,812,828 | 2,663,263 | 06/30/2020 |
| 46641TCA0 | 5,254,243 | 4,815,065 | 439,177 | 4,815,065 | 4,815,065 | 06/30/2020 |
| 61748Hqw4 | 6,729,067 | 6,660,377 | 68,689 | 6,660,377 | 6,660,377 | 06/30/2020 |
| 61748HUF6 | 14,550,464 | 13,739,179 | 811,285 | 13,739,179 | 13,739,179 | 06/30/2020 |
| 61748HWP2 | 5,510,526 | 5,314,889 | 195,637 | 5,314,889 | 5,314,889 | 06/30/2020 |
| 61748HYQ8 | 17,182,046 | 16,393,107 | 788,939 | 16,393,107 | 16,393,107 | 06/30/2020 |
| 61761PAL9 | 6,801,855 | 6,771,857 | 29,999 | 6,771,857 | 6,771,857 | 06/30/2020 |
| 61762LBJ1 | 10,197,916 | 8,888,803 | 1,309,114 | 8,888,803 | 8,888,803 | 06/30/2020 |
| 61690PAK7 | 12,578,801 | 12,436,166 | 142,636 | 12,436,166 | 12,436,166 | 06/30/2020 |
| 61762UCQ4 | 3,422,475 | 3,338,001 | 84,474 | 3,338,001 | 3,273,924 | 06/30/2020 |
| 65540XAJ6 | 9,594,456 | 9,478,656 | 115,800 | 9,478,656 | 9,428,374 | 06/30/2020 |
| 65540XAJ6 | 4,042,867 | 3,994,040 | 48,827 | 3,994,040 | 3,973,156 | 06/30/2020 |
| 45660LDR7 | 2,373,532 | 2,145,212 | 228,321 | 2,145,212 | 2,076,616 | 06/30/2020 |
| 86359LHX0 | 4,578,955 | 4,183,038 | 395,917 | 4,183,038 | 4,183,038 | 06/30/2020 |
| 86359DRS8 | 5,414,206 | 5,063,772 | 350,434 | 5,063,772 | 5,063,772 | 06/30/2020 |
| 86359DRS8 | 2,670,451 | 2,497,606 | 172,845 | 2,497,606 | 2,497,606 | 06/30/2020 |
| 81744LAN4 | 3,444,308 | 3,393,545 | 50,763 | 3,393,545 | 3,351,012 | 06/30/2020 |
| 87222PAB9 | 1,508,284 | 1,394,424 | 113,860 | 1,394,424 | 1,394,424 | 06/30/2020 |
| 136040AA0 | 20,504,491 | 15,822,495 | 4,681,996 | 15,822,495 | 15,822,495 | 06/30/2020 |
| 95000MAQ4 | 876,547 | 413,603 | 462,944 | 413,603 | 387,204 | 09/30/2020 |
| 61748HvH1 | 2,405,192 | 2,356,405 | 48,787 | 2,356,405 | 2,274,977 | 09/30/2020 |

Notes to the Financial Statements

5. Investments (Continued)

| (1) | (2) | (3) | (4) | (5) | (6) | (7) |
|-------------------|---------------------------------------------------------------------------------|---------------------------------------------|-----------------|------------------------------|-------------------------------|--------------------------------------------------|
| CUSIP | Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI | Present Value of Projected Cash Flows | Recognized OTTI | Amortized Cost After OTTI | Fair Value at Time of OTTI | Date of Financial Statement Where Reported |
| ..058933AG7 | 1,598,060 | 1,557,820 | 40,240 | 1,557,820 | 1,557,820 | 09/30/2020 |
| ..885220DS9 | 675,741 | 640,125 | 35,616 | 640,125 | 628,125 | 09/30/2020 |
| ..17322JAD5 | 11,027,203 | 10,952,384 | 74,819 | 10,952,384 | 10,825,612 | 09/30/2020 |
| ..12669GRQ6 | 4,279,425 | 4,206,791 | 72,634 | 4,206,791 | 4,206,791 | 09/30/2020 |
| ..12669GSN2 | 4,314,870 | 4,255,359 | 59,511 | 4,255,359 | 4,255,359 | 09/30/2020 |
| Total | | | \$ 22,002,188 | | | |

(4) All impaired securities for which an OTTI has not been recognized in earnings as a realized loss

The following table shows the gross unrealized losses and fair values of loan-backed securities, which have not been impaired to fair value, aggregated by length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2020:

- a. The aggregate amount of unrealized losses:

1. Less than 12 months \$... 179,495,126

2. 12 months or longer 154,555,732
- b. The aggregate related fair value of securities with unrealized losses:

1. Less than 12 months \$ 3,626,775,710

2. 12 months or longer 1,917,488,123

(5) A full analysis of all relevant qualitative considerations was completed in reaching the conclusion that the impairments were not other-than-temporary, including the intent and ability to hold the investment for a period of time sufficient to allow for a recovery in value. Specific events that may influence the operations of the issuer and impaired earnings potential are reviewed in addition to length of time and extent to which the fair value has been less than cost.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions - None

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Taker - Overview of Secured Borrowing Transactions

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral

The Company participates in repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company lends bonds and receives cash as collateral. The Company monitors the estimated fair value of the collateral and the securities loaned throughout the duration of the contract and contributes additional collateral as necessary. Securities loaned under these agreements may be sold or re-pledged by the transferee.

(2) Type of repo trades used

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|-----------------------------|---------------|----------------|---------------|----------------|
| a. Bilateral (Yes/No) | YES | YES | YES | |
| b. Tri-Party (Yes/No) | NO | NO | NO | |

(3) Original (flow) & residual maturity

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|-----------------------------------|-------------------|-------------------|-------------------|----------------|
| a. Maximum Amount | | | | |
| 1. Open - No maturity | \$ | \$ | \$ | \$ |
| 2. Overnight | | | | |
| 3. 2 days to 1 week | | | | |
| 4. Over 1 week to 1 month | | | | |
| 5. Over 1 month to 3 months | 143,620,000 | 303,270,000 | 303,270,000 | |
| 6. Over 3 months to 1 year | 616,343,000 | 313,073,000 | 313,073,000 | |
| 7. Over 1 year | | 598,283,704 | 598,358,554 | |
| b. Ending Balance | | | | |
| 1. Open - No maturity | \$ | \$ | \$ | \$ |
| 2. Overnight | | | | |
| 3. 2 days to 1 week | | | | |
| 4. Over 1 week to 1 month | | | 313,073,000 | |
| 5. Over 1 month to 3 months | 143,620,000 | 303,270,000 | | |
| 6. Over 3 months to 1 year | 616,343,000 | 313,073,000 | | |
| 7. Over 1 year | | 598,283,704 | 598,358,554 | |

(4) Fair value of securities sold and/or acquired that resulted in default

The Company did not have any securities sold or outstanding for which the repurchase agreement defaulted as of September 30, 2020.

Notes to the Financial Statements

5. Investments (Continued)

(5) Securities "sold" under repo - secured borrowing

| | | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|----|------------------------------|----------------|------------------|------------------|----------------|
| a. | Maximum Amount | | | | |
| 1. | BACV | XXX | XXX | XXX | \$ |
| 2. | Nonadmitted - Subset of BACV | XXX | XXX | XXX | \$ |
| 3. | Fair Value | \$ 859,552,346 | \$ 1,396,004,968 | \$ 1,396,004,968 | \$ |
| b. | Ending Balance | | | | |
| 1. | BACV | XXX | XXX | XXX | \$ |
| 2. | Nonadmitted - Subset of BACV | XXX | XXX | XXX | \$ |
| 3. | Fair Value | \$ 859,552,346 | \$ 1,396,004,968 | \$ 1,036,112,925 | \$ |

(6) Securities sold under repo - secured borrowing by NAIC designation

| Ending Balance | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
|---------------------------------|------|----------------|----------------|--------------|--------|--------|--------|-------------|
| | None | NAIC 1 | NAIC 2 | NAIC 3 | NAIC 4 | NAIC 5 | NAIC 6 | Nonadmitted |
| a. Bonds - BACV | \$ | \$ 490,467,874 | \$ 381,174,510 | \$ 1,996,605 | \$ | \$ | \$ | \$ |
| b. Bonds - FV | | 595,152,868 | 438,809,722 | 2,150,335 | | | | |
| c. LB & SS - BACV | | | | | | | | |
| d. LB & SS - FV | | | | | | | | |
| e. Preferred stock - BACV | | | | | | | | |
| f. Preferred stock - FV | | | | | | | | |
| g. Common stock | | | | | | | | |
| h. Mortgage loans - BACV | | | | | | | | |
| i. Mortgage loans - FV | | | | | | | | |
| j. Real estate - BACV | | | | | | | | |
| k. Real estate - FV | | | | | | | | |
| l. Derivatives - BACV | | | | | | | | |
| m. Derivatives - FV | | | | | | | | |
| n. Other invested assets - BACV | | | | | | | | |
| o. Other invested assets - FV | | | | | | | | |
| p. Total assets - BACV | \$ | \$ 490,467,874 | \$ 381,174,510 | \$ 1,996,605 | \$ | \$ | \$ | \$ |
| q. Total assets - FV | \$ | \$ 595,152,868 | \$ 438,809,722 | \$ 2,150,335 | \$ | \$ | \$ | \$ |
| p = (a+c+e+g+h+j+l+n) | | | | | | | | |
| q = (b+d+f+g+i+k+m+o) | | | | | | | | |

(7) Collateral received - secured borrowing

| | | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|----|-----------------|----------------|------------------|------------------|----------------|
| a. | Maximum Amount | | | | |
| 1. | Cash | \$ 759,963,000 | \$ 1,214,626,704 | \$ 1,214,701,554 | \$ |
| 2. | Securities (FV) | | | | |
| b. | Ending Balance | | | | |
| 1. | Cash | \$ 759,963,000 | \$ 1,214,626,704 | \$ 911,431,554 | \$ |
| 2. | Securities (FV) | | | | |

(8) Cash & non-cash collateral received - secured borrowing by NAIC designation

| Ending Balance | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
|------------------------------------------------------|----------------|--------|--------|--------|--------|--------|--------|------------------------------|
| | None | NAIC 1 | NAIC 2 | NAIC 3 | NAIC 4 | NAIC 5 | NAIC 6 | Does Not Qualify as Admitted |
| a. Cash | \$ 911,431,554 | \$ | \$ | \$ | \$ | \$ | \$ | \$ |
| b. Bonds - FV | | | | | | | | |
| c. LB & SS - FV | | | | | | | | |
| d. Preferred stock - FV | | | | | | | | |
| e. Common stock | | | | | | | | |
| f. Mortgage loans - FV | | | | | | | | |
| g. Real estate - FV | | | | | | | | |
| h. Derivatives - FV | | | | | | | | |
| i. Other Invested Assets - FV | | | | | | | | |
| j. Total collateral assets - FV (sum of a through i) | \$ 911,431,554 | \$ | \$ | \$ | \$ | \$ | \$ | \$ |

Notes to the Financial Statements

5. Investments (Continued)

(9) Allocation of aggregate collateral by remaining contractual maturity

| | Fair Value |
|-----------------------------------|-------------|
| a. Overnight and continuous | \$ |
| b. 30 Days or less | 313,073,000 |
| c. 31 to 90 Days | |
| d. More than 90 days | 598,358,554 |

(10) Allocation of aggregate collateral reinvested by remaining contractual maturity

| | Amortized Cost | Fair Value |
|----------------------------|-------------------|-------------------|
| a. 30 Days or less | \$... 911,431,554 | \$... 911,431,554 |
| b. 31 to 60 Days | | |
| c. 61 to 90 Days | | |
| d. 91 to 120 Days | | |
| e. 121 to 180 Days | | |
| f. 181 to 365 Days | | |
| g. 1 to 2 Years | | |
| h. 2 to 3 Years | | |
| i. More than 3 years | | |

(11) Liability to return collateral - secured borrowing (total)

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|-------------------------------------|-------------------|------------------|-------------------|----------------|
| a. Maximum Amount | | | | |
| 1. Cash (Collateral - All) | \$... 759,963,000 | \$ 1,214,626,704 | \$ 1,214,701,554 | \$ |
| 2. Securities Collateral (FV) | | | | |
| b. Ending Balance | | | | |
| 1. Cash (Collateral - All) | \$... 759,963,000 | \$ 1,214,626,704 | \$... 911,431,554 | \$ |
| 2. Securities Collateral (FV) | | | | |

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Provider - Overview of Secured Borrowing Transactions

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral

Included in short-term investments are amounts receivable under reverse repurchase agreements, which involves the purchase of investments from a seller with the agreement that the investments will be repurchased by the seller at a specified price, and at a specified date or within a specified period of time, not to exceed 364 days. The investments purchased, which represent collateral on a secured lending arrangement, are not reflected in the Company's consolidated balance sheets. Instead, the secured lending arrangement is reflected as a short-term investment for the principal amount loaned under the agreement. There were no amounts loaned under reverse repurchase agreements at September 30, 2020.

(2) Type of repo trades used

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|-----------------------------|---------------|----------------|---------------|----------------|
| a. Bilateral (Yes/No) | YES | YES | | |
| b. Tri-Party (Yes/No) | NO | NO | | |

(3) Original (flow) & residual maturity

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|-----------------------------------|---------------|----------------|---------------|----------------|
| a. Maximum Amount | | | | |
| 1. Open - No maturity | \$ | \$ | \$ | \$ |
| 2. Overnight | | | | |
| 3. 2 days to 1 week | | | | |
| 4. Over 1 week to 1 month | 85,000,000 | 85,000,000 | | |
| 5. Over 1 month to 3 months | | | | |
| 6. Over 3 months to 1 year | | | | |
| 7. Over 1 year | | | | |
| b. Ending Balance | | | | |
| 1. Open - No maturity | \$ | \$ | \$ | \$ |
| 2. Overnight | | | | |
| 3. 2 days to 1 week | | | | |
| 4. Over 1 week to 1 month | 85,000,000 | | | |
| 5. Over 1 month to 3 months | | | | |
| 6. Over 3 months to 1 year | | | | |
| 7. Over 1 year | | | | |

(4) Fair value of securities sold and/or acquired that resulted in default - None

Notes to the Financial Statements

5. Investments (Continued)

(5) Fair value of securities acquired under repo - secured borrowing

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|-------------------|---------------|----------------|---------------|----------------|
| a. Maximum Amount | \$ 85,000,000 | \$ 85,000,000 | \$ | \$ |
| b. Ending Balance | \$ 85,000,000 | \$ | \$ | \$ |

(6) Securities acquired under repo - secured borrowing by NAIC designation - None

(7) Collateral provided - secured borrowing

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|------------------------------|---------------|----------------|---------------|----------------|
| a. Maximum Amount | | | | |
| 1. Cash | \$ - | \$ | \$ | \$ |
| 2. Securities (FV) | 275,430,848 | 275,430,848 | | |
| 3. Securities (BACV) | XXX | XXX | XXX | XXX |
| 4. Nonadmitted Subset (BACV) | XXX | XXX | XXX | XXX |
| b. Ending Balance | | | | |
| 1. Cash | \$ - | \$ | \$ | \$ |
| 2. Securities (FV) | 275,430,848 | | | |
| 3. Securities (BACV) | 275,430,848 | | | |
| 4. Nonadmitted Subset (BACV) | - | | | |

(8) Allocation of aggregate collateral pledged by remaining contractual maturity - None

(9) Recognized receivable for return of collateral - secured borrowing

| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
|--------------------|---------------|----------------|---------------|----------------|
| a. Maximum Amount | | | | |
| 1. Cash | \$ | \$ | \$ | \$ |
| 2. Securities (FV) | 85,000,000 | 85,000,000 | | |
| b. Ending Balance | | | | |
| 1. Cash | \$ | \$ | \$ | \$ |
| 2. Securities (FV) | 85,000,000 | | | |

(10) Recognized liability to return collateral - secured borrowing (total) - None

H. Repurchase Agreements Transactions Accounted for as a Sale - None

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale - None

J. Real Estate - No Significant Changes

K. Low-Income Housing Tax Credits (LIHTC) - None

L. Restricted Assets - No Significant Changes

M. Working Capital Finance Investments - None

N. Offsetting and Netting of Assets and Liabilities - None

O. 5GI Securities - No Significant Changes

P. Short Sales - None

Q. Prepayment Penalty and Acceleration Fees - No Significant Changes

6. Joint Ventures, Partnerships and Limited Liability Companies - No Significant Changes

7. Investment Income - No Significant Changes

8. Derivative Instruments

A. Derivatives under SSAP No. 86 - Derivatives

(1) Discussion - No Significant Changes

(2) Description of Objectives - No Significant Changes

(3) Description of Accounting Policies - No Significant Changes

(4) Derivative Contracts with Financing Premiums - No Significant Changes

(5) Net Gain or Loss Recognized - No Significant Changes

(6) Net Gain or Loss Recognized from Derivatives No Longer Qualifying for Hedge Accounting - No Significant Changes

(7) Derivatives Accounted for as Cash Flow Hedges of a Forecasted Transaction - No Significant Changes

(8) Premium Cost for Derivative Contracts - None

Notes to the Financial Statements

8. Derivative Instruments (Continued)

B. Derivatives under SSAP No. 108 - Derivative Hedging Variable Annuity Guarantees (Life/Fraternal Only) - None

9. Income Taxes - No Significant Changes

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. Some employees of the Company and Athene Employee Services LLC participate in one or more Share Award Agreements (the Agreements) sponsored by Athene Holding Ltd. (AHL), an indirect parent of the Company, for which the Company has no legal obligation. Salary expense of the Company and of Athene Employee Services LLC is allocated through the Shared Services Agreement. Under SSAP No. 104R, *Share-Based Payments*, the stock compensation expense associated with the Agreements that would have been allocated to the Company is required to be recorded as a capital contribution to the reporting entity. The Company has allocated the stock compensation expense associated with the Agreements based on the same methodology as the Shared Services Agreement. In accordance with SSAP No. 104R, the Company incurred expense and recorded a capital contribution under the Agreements totaling \$6.7 million and \$9.9 million for the nine months ended September 30, 2020 and for the year ended December 31, 2019, respectively, which includes amounts contributed by the Company to downstream insurance subsidiaries.
- B. Detail of Transactions Greater Than 0.5% of Admitted Assets - No Significant Changes
- C. Amount of Transactions & Effects of Change in Terms of Intercompany Arrangements - No Significant Changes
- D. Amounts Due To or From Related Parties - No Significant Changes
- E. Guarantees or Contingencies - No Significant Changes
- F. Management Service Contracts and Cost Sharing Arrangements - No Significant Changes
- G. Nature of Relationships that Could Affect Operations - No Significant Changes
- H. Amount Deducted for Investment in Upstream Company - None
- I. Detail of Investments in Affiliates Greater Than 10% of Admitted Assets - No Significant Changes
- J. Write-Down for Impairments of Investments in Subsidiary Controlled or Affiliated Companies - No Significant Changes
- K. Foreign Subsidiary Value Using CARVM - No Significant Changes
- L. Downstream Holding Company Value Using Look-Through Method - No Significant Changes
- M. All SCA Investments - No Significant Changes
- N. Investment in Insurance SCAs - No Significant Changes
- O. SCA and SSAP No. 48 Entity Loss Tracking - None

11. Debt

- A. Debt, Including Capital Notes - No Significant Changes
- B. FHLB (Federal Home Loan Bank) Agreements
 - (1) The Company is a member of the FHLB of Des Moines. Through its membership, the Company is eligible to borrow under variable rate short-term federal fund arrangements to provide additional liquidity. These borrowings are accounted for as borrowed money under SSAP No. 15, *Debt and Holding Company Obligations*. During 2019, the Company borrowed \$50.0 million in the general account and \$425.0 million in the separate account with an interest rate of 1.8%. As of May 2020, all \$475.0 million in borrowings have matured. The Company incurred interest expense on the short-term borrowings of \$2.7 million and \$1.1 million in the general and separate account for the nine months ended September 30, 2020 and for the year ended December 31, 2019, respectively.

The Company has issued separate account funding agreements to the FHLB of Des Moines in exchange for cash resulting in a liability of \$2.0 billion as of September 30, 2020. The Company uses these funds in an investment spread strategy, consistent with its other investment spread operations. As such, the Company applies SSAP No. 52, *Deposit-Type Contracts*, accounting treatment to these funds, consistent with its other deposit-type contracts. It is not part of the Company’s strategy to utilize these funds for operations, and any funds obtained from the FHLB of Des Moines for use in general operations would be accounted for consistent with SSAP No. 15 as borrowed money.

The Company must provide appropriate collateral to borrow under the arrangements described above. The borrowing capacity available to the Company under these agreements is largely a factor of the Company’s ability to post eligible collateral, as well as internal limits such as single-holder exposure limits (10% of the entity’s balance sheet liabilities) and NAIC capital requirements.

The tables below indicate the amount of FHLB of Des Moines stock purchased, collateral pledged, assets and liabilities related to the agreements with FHLB of Des Moines.

Notes to the Financial Statements

11. Debt (Continued)

(2) FHLB capital stock

(a) Aggregate totals

| | (1) Total (2+3) | (2) General Account | (3) Separate Accounts |
|-------------------------------------------------------------------------|-----------------------|---------------------------|-----------------------------|
| 1. Current Year | | | |
| (a) Membership stock - Class A | \$ | \$ | \$ |
| (b) Membership stock - Class B | 10,000,000 | 10,000,000 | |
| (c) Activity stock | 84,048,000 | 84,048,000 | |
| (d) Excess stock | | | |
| (e) Aggregate total (a+b+c+d) | \$ 94,048,000 | \$ 94,048,000 | \$ |
| (f) Actual or estimated borrowing capacity as determined by the insurer | \$ 3,000,000,000 | | |
| 2. Prior Year-End | | | |
| (a) Member stock - Class A | \$ | \$ | \$ |
| (b) Membership stock - Class B | 10,000,000 | 10,000,000 | |
| (c) Activity stock | 68,048,000 | 68,048,000 | |
| (d) Excess stock | | | |
| (e) Aggregate total (a+b+c+d) | \$ 78,048,000 | \$ 78,048,000 | \$ |
| (f) Actual or estimated borrowing capacity as determined by the insurer | \$ 1,900,000,000 | | |

(b) Membership stock (class A and B) eligible and not eligible for redemption

| Membership Stock | (1) Current Year Total (2+3+4+5+6) | (2) Not Eligible for Redemption | Eligible for Redemption | | | |
|------------------|------------------------------------------|---------------------------------------|------------------------------|----------------------------------------|----------------------------------|---------------------|
| | | | (3) Less Than 6 Months | (4) 6 Months to Less Than 1 Year | (5) 1 to Less Than 3 Years | (6) 3 to 5 Years |
| 1. Class A | \$ | \$ | \$ | \$ | \$ | \$ |
| 2. Class B | \$ 10,000,000 | \$ 10,000,000 | \$ | \$ | \$ | \$ |

(3) Collateral pledged to FHLB

(a) Amount pledged as of reporting date

| | (1) Fair Value | (2) Carrying Value | (3) Aggregate Total Borrowing |
|------------------------------------------------------------------------------------------|-------------------|-----------------------|-------------------------------------|
| 1. Current year total general and separate accounts total collateral pledged (Lines 2+3) | \$ 2,875,229,469 | \$ 2,814,479,205 | \$ 2,101,200,000 |
| 2. Current year general account total collateral pledged | 2,875,229,469 | 2,814,479,205 | |
| 3. Current year separate accounts total collateral pledged | | | 2,101,200,000 |
| 4. Prior year-end total general and separate accounts total collateral pledged | 1,802,768,492 | 1,729,088,342 | 1,701,200,000 |

(b) Maximum amount pledged during reporting period

| | (1) Fair Value | (2) Carrying Value | (3) Amount Borrowed at Time of Maximum Collateral |
|--------------------------------------------------------------------------------------------|-------------------|-----------------------|------------------------------------------------------------|
| 1. Current year total general and separate accounts maximum collateral pledged (Lines 2+3) | \$ 2,875,229,469 | \$ 2,814,479,205 | \$ 2,101,200,000 |
| 2. Current year general account maximum collateral pledged | 2,875,229,469 | 2,814,479,205 | |
| 3. Current year separate accounts maximum collateral pledged | | | 2,101,200,000 |
| 4. Prior year-end total general and separate accounts maximum collateral pledged | 1,802,768,492 | 1,729,088,342 | 1,701,200,000 |

Notes to the Financial Statements

11. Debt (Continued)

- (4) Borrowing from FHLB
- (a) Amount as of the reporting date

| | (1) | (2) | (3) | (4) |
|-----------------------------|------------------|-----------------|-------------------|-----------------------------------------|
| | Total (2+3) | General Account | Separate Accounts | Funding Agreements Reserves Established |
| 1. Current Year | | | | |
| (a) Debt | \$ | \$ | \$ | XXX |
| (b) Funding agreements | 2,101,200,000 | | 2,101,200,000 | \$ 2,009,928,869 |
| (c) Other | | | | XXX |
| (d) Aggregate total (a+b+c) | \$ 2,101,200,000 | \$ | \$ 2,101,200,000 | \$ 2,009,928,869 |
| 2. Prior Year-end | | | | |
| (a) Debt | \$ 475,000,000 | \$ 50,000,000 | \$ 425,000,000 | XXX |
| (b) Funding agreements | 1,226,200,000 | | 1,226,200,000 | \$ 1,194,642,685 |
| (c) Other | | | | XXX |
| (d) Aggregate total (a+b+c) | \$ 1,701,200,000 | \$ 50,000,000 | \$ 1,651,200,000 | \$ 1,194,642,685 |

- (b) Maximum amount during reporting period (current year)

| | (1) | (2) | (3) |
|----------------------------------|------------------|-----------------|-------------------|
| | Total (2+3) | General Account | Separate Accounts |
| 1. Debt | \$ 475,000,000 | \$ 50,000,000 | \$ 425,000,000 |
| 2. Funding agreements | 2,101,200,000 | | 2,101,200,000 |
| 3. Other | | | |
| 4. Aggregate total (Lines 1+2+3) | \$ 2,576,200,000 | \$ 50,000,000 | \$ 2,526,200,000 |

11B(4)b4 (Columns 1, 2 and 3) should be equal to or greater than 11B(4)a1(d) (Columns 1, 2 and 3 respectively)

- (c) FHLB - Prepayment obligations

| | Does the company have prepayment obligations under the following arrangements (YES/NO)? |
|-----------------------|-----------------------------------------------------------------------------------------|
| 1. Debt | NO |
| 2. Funding agreements | YES |
| 3. Other | NO |

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

- A. Defined Benefit Plan - None
- B. Investment Policies and Strategies of Plan Assets - None
- C. Fair Value of Each Class of Plan Assets - None
- D. Expected Long-Term Rate of Return for the Plan Assets - None
- E. Defined Contribution Plans - None
- F. Multiemployer Plans - None
- G. Consolidated/Holding Company Plans - No Significant Changes
- H. Postemployment Benefits and Compensated Absences - No Significant Changes
- I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17) - None

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

1. Outstanding Shares - No Significant Changes
2. Dividend Rate of Preferred Stock - None
3. Effective January 30, 2020, the Company's parent, Athene Annuity & Life Assurance Company (AADE), entered into a Capital Maintenance Agreement to provide capital support to the Company, in an amount sufficient to satisfy the insurance laws of the State of New Jersey, in order to obtain authority for the Company to issue registered index-linked annuities in New Jersey. The agreement will remain in effect for ten years.
4. Ordinary Dividends - No Significant Changes
5. Company Profits Paid as Ordinary Dividends - No Significant Changes
6. Surplus Restrictions - No Significant Changes
7. Surplus Advances - None
8. Stock Held for Special Purposes - None
9. Changes in Special Surplus Funds - None

Notes to the Financial Statements

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations (Continued)

10. Unassigned funds (surplus) - No Significant Changes
11. Company-Issued Surplus Debentures or Similar Obligations - None
12. Impact of Any Restatement Due to Prior Quasi-Reorganizations - None
13. Effective Date(s) of Quasi-Reorganizations in the Prior 10 Years - No Significant Changes

14. Liabilities, Contingencies and Assessments

- A. Contingent Commitments - No Significant Changes
- B. Assessments - No Significant Changes
- C. Gain Contingencies - None
- D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits - None
- E. Joint and Several Liabilities - None
- F. All Other Contingencies

Corporate-owned Life Insurance (COLI) Matter - In 2000 and 2001, two insurance companies which were subsequently merged into AAIA, purchased broad based variable COLI policies from American General Life Insurance Company (American General) that, as of September 30, 2020, had an asset value of \$401.0 million, and is included in other assets on the consolidated balance sheets. In January 2012, the COLI policy administrator delivered to AAIA a supplement to the existing COLI policies and advised that American General and ZC Resource Investment Trust (ZC Trust) had unilaterally implemented changes set forth in the supplement that if effective, would: (1) potentially negatively impact the crediting rate for the policies and (2) change the exit and surrender protocols set forth in the policies. In March 2013, AAIA filed suit against American General, ZC Trust, and ZC Resource LLC in Chancery Court in Delaware, seeking, among other relief, a declaration that the changes set forth in the supplement were ineffectual and in breach of the parties' agreement. The parties filed cross motions for judgment as a matter of law, and the court granted defendants' motion and dismissed without prejudice on ripeness grounds. The issue that negatively impacts the crediting rate for one of the COLI policies has subsequently been triggered and on April 3, 2018, we filed suit against the same defendants in Chancery Court in Delaware seeking substantially similar relief. Defendants moved to dismiss and the Court heard oral arguments on February 13, 2019, The Court issued an opinion on July 31, 2019 that did not address the merits, but found that Chancery Court did not have jurisdiction over our claims and directed us to either amend our complaint or transfer the matter to Delaware Superior Court. The matter has been transferred to the Delaware Superior Court. Defendants renewed their motion to dismiss and the Superior Court heard oral arguments on December 18, 2019. The Superior Court issued an opinion on May 18, 2020 in which it granted in part and denied in part defendants' motion. The Superior Court denied defendants' motion with respect to the issue that negatively impacts the crediting rate for one of the COLI policies, which issue will proceed to discovery. The Superior Court granted defendants' motion and dismissed without prejudice on ripeness grounds claims related to the exit and surrender protocols set forth in the policies, and dismissed defendant ZC Resource LLC. If the supplement is ultimately deemed to be effective, the purported changes to the policies could impair AAIA's ability to access the value of guarantees associated with the policies. The parties have served initial document requests and interrogatories and are currently in the early stages of discovery. The Court issued a scheduling order on November 10, 2020 setting forth various case deadlines and a July 11, 2022 trial date. The value of the guarantees included within the asset value reflected above is \$195.9 million as of September 30, 2020.

Regulatory Matters - The Company and certain of its insurance subsidiaries have experienced increased service and administration complaints related to the conversion and administration of the block of life insurance business acquired in connection with Athene Holding Ltd.'s acquisition of Aviva USA Corporation (Aviva USA) and reinsured to affiliates of Global Atlantic Financial Group Ltd. The life insurance policies included in this block have been and are currently being administered by AllianceOne, a subsidiary of DXC Technology Company, which was retained by such Global Atlantic affiliates to provide third party administration services on such policies. AllianceOne also administers a small block of annuity policies that were on Aviva USA's legacy policy administration systems that were also converted in connection with the acquisition of Aviva USA and have experienced similar service and administration issues, but to a lesser degree.

As a result of the difficulties experienced with respect to the administration of such policies, Athene has received notifications from several state regulators, including but not limited to the New York State Department of Financial Services (NYSDFS), the California Department of Insurance (CDI) and the Texas Department of Insurance, indicating, in each case, that the respective regulator planned to undertake a market conduct examination or enforcement proceeding of the Company or one of its subsidiaries, as applicable, relating to the treatment of policyholders subject to Athene reinsurance agreements with affiliates of Global Atlantic and the conversion of the life and annuity policies, including the administration of such blocks by AllianceOne. The Company, and its subsidiary, Athene Life Insurance Company of New York (ALICNY), have entered into consent orders with regulators of several states, including the NYSDFS and the CDI, to resolve the underlying matters in those states. All fines and costs, including those associated with remediation plans, paid in connection with the consent orders were subject to indemnification by Global Atlantic or affiliates of Global Atlantic.

In addition to the examinations and proceedings initiated to date, it is possible that other regulators may pursue similar formal examinations, inquiries or enforcement proceedings and that any examinations, inquiries and/or enforcement proceedings may result in fines, administrative penalties and payments to policyholders. The Company is not currently able to estimate the amount of any such fines, penalties or payments arising from these matters with reasonable certainty, but it is possible that such amounts may be material.

Pursuant to the terms of the reinsurance agreements between Athene and the relevant affiliates of Global Atlantic, the applicable affiliates of Global Atlantic have financial responsibility for the ceded life block and are subject to significant administrative service requirements, including compliance with applicable law. The agreements also provide for indemnification to Athene, including for administration issues.

On January 23, 2019, the Company received a letter from the NYSDFS, with respect to a recent Pension Risk Transfer (PRT) transaction, which expressed concerns with the Company's interpretation and reliance upon certain exemptions from licensing in New York in connection with certain activities performed by employees in the PRT channel, including specific activities performed within New York. On April 13, 2020 the Company entered into a consent order with the NYSDFS to resolve this matter. Pursuant to the consent order, the NYSDFS imposed a fine of \$45 million, which was accrued by the Company as of December 31, 2019 and paid on April 22, 2020.

Fiduciary Standards - The U.S. Securities and Exchange Commission (SEC), NAIC, and several states have taken action or are exploring options around a fiduciary standard or best interest standard that may impact the Company and its subsidiaries. If these rules do not align, the distribution of products by the Company and its subsidiaries could be further complicated.

On June 5, 2019, the SEC adopted a rulemaking package designed to enhance the quality and transparency of retail investors' relationships with investment advisers and broker-dealers. The rule package is effective on September 10, 2019 with a compliance date of June 30, 2020. The rulemaking package included: Regulation Best Interest - the Broker-Dealer Standard of Conduct; the new Form CRS Relationship Summary; and two separate interpretations under the Investment Advisers Act of 1940. The Company believe the Regulation may impact the distribution of the Company's and its subsidiaries' products through third party broker-dealers that distribute the products to retail customers, the impact of which is still being determined.

Notes to the Financial Statements

14. Liabilities, Contingencies and Assessments (Continued)

On February 13, 2020, the NAIC adopted an updated version of the Suitability in Annuity Transactions Model Regulation to include a best interest obligation. Iowa is on track to become the first state to adopt the Model by way of regulation. The Company is evaluating the regulation, which is expected to affect the distribution of products by the Company and its subsidiaries. On July 17, 2018, NYDFS amended a Regulation 187, Suitability and Best Interests in Life Insurance and Annuity Transactions, adopting a "best interest" standard for those licensed to sell life insurance and annuity products in New York. The regulation became effective on annuity transactions on August 1, 2019 and the Company's subsidiary, Athene Annuity & Life Assurance Company of New York (AANY), has taken appropriate actions to comply with the regulation's requirements. The regulation became effective for life insurance transactions on February 1, 2020.

In addition to the cases previously discussed, the Company is routinely involved in litigation and other proceedings, reinsurance claims and regulatory proceedings arising in the ordinary course of its business. At present, no contingencies related to pending litigation and regulatory matters are considered material in relation to the financial position of the Company.

15. Leases - None

16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk - No Significant Changes

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities - None

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans - None

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators - None

20. Fair Value Measurements

A. Fair Value Measurement

(1) Fair value measurements at reporting date

| Description for each class of asset or liability | Level 1 | Level 2 | Level 3 | Net Asset Value (NAV) | Total |
|--------------------------------------------------|---------------|----------------|---------------|-----------------------|----------------|
| a. Assets at fair value | | | | | |
| Bonds: Corporate | \$ | \$ 188,131 | \$ | \$ | \$ 188,131 |
| Bonds: CMBS | | 4,027,152 | 1,114,764 | | 5,141,915 |
| Bonds: RMBS | | 884,928 | | | 884,928 |
| Preferred stock affiliated | | | 27,567,613 | | 27,567,613 |
| Common stocks unaffiliated | 27,371,340 | 94,048,358 | 25,969,114 | | 147,388,812 |
| Derivative assets: Options | | 31,416,841 | | | 31,416,841 |
| Derivative assets: Currency swaps | | 1,483,310 | | | 1,483,310 |
| Derivative assets: Total Return Swaps | | 1,347,667 | | | 1,347,667 |
| Derivative assets: Futures | 24,663,834 | | | | 24,663,834 |
| Derivative assets: Forwards | | 8,936,823 | | | 8,936,823 |
| Separate account assets: Variable products | | 29,957,081 | | | 29,957,081 |
| Total assets at fair value/NAV | \$ 52,035,174 | \$ 172,290,292 | \$ 54,651,491 | \$ | \$ 278,976,957 |
| b. Liabilities at fair value | | | | | |
| Derivative liabilities: Options | \$ | \$ 10,890,018 | \$ | \$ | \$ 10,890,018 |
| Derivative liabilities: Interest rate swaps | 178,797 | 2,186,196 | | | 2,364,993 |
| Derivative liabilities: Total Return Swaps | | 206,142 | | | 206,142 |
| Derivative liabilities: Futures | 4,071,384 | | | | 4,071,384 |
| Derivative liabilities: Forwards | | 2,481,497 | | | 2,481,497 |
| Separate account liabilities: Variable products | | 29,956,599 | | | 29,956,599 |
| Total liabilities at fair value | \$ 4,250,180 | \$ 45,720,452 | \$ | \$ | \$ 49,970,632 |

(2) Fair value measurements in Level 3 of the fair value hierarchy

| Description | Ending balance as of 06/30/2020 | Transfers Into Level 3 | Transfers Out of Level 3 | Total Gains and (Losses) Included in Net Income | Total Gains and (Losses) Included in Surplus | Purchases | Issuances | Sales | Settlements | Ending Balance for 09/30/2020 |
|----------------------------|---------------------------------|------------------------|--------------------------|-------------------------------------------------|----------------------------------------------|---------------|-----------|--------------|-------------|-------------------------------|
| a. Assets | | | | | | | | | | |
| Bonds: CMBS | \$ 686,958 | \$ 387,204 | \$ | \$ 20,152 | \$ 20,450 | \$ | \$ | \$ | \$ | \$ 1,114,764 |
| Preferred stock affiliated | 27,876,433 | | | | 300,272 | | | (609,091) | | 27,567,613 |
| Common stocks unaffiliated | 11,493,066 | | | (3,228,197) | 7,276,422 | 10,427,823 | | | | 25,969,114 |
| Total assets | \$ 40,056,456 | \$ 387,204 | \$ | \$ (3,208,044) | \$ 7,597,143 | \$ 10,427,823 | \$ | \$ (609,091) | \$ | \$ 54,651,491 |
| b. Liabilities | | | | | | | | | | |
| Total liabilities | \$ | \$ | \$ | \$ | \$ | \$ | \$ | \$ | \$ | \$ |

Transfers into and out of Level 3 are represented by NAIC Class 6 securities which are carried at lower of cost or fair value resulting in periodic transfers into and out of Level 3 financial instruments which are characterized as carried at fair value.

(3) Transfers between fair value hierarchy levels are recognized at the end of the period in which the transfer occurs.

(4) The following discussion describes the valuation methodologies and inputs used for assets and liabilities measured and disclosed at fair value. The techniques utilized in estimating the fair values of financial instruments are reliant on the assumptions used.

Notes to the Financial Statements

20. Fair Value Measurements (Continued)

Fair value estimates are based on quoted market prices when available. When quoted market prices are not available, the Company utilizes commercially available pricing vendors that utilize observable market inputs, like recent trading activity, to derive fair value. When vendor prices are not available, fair value is generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality (matrix pricing). In instances where there is little or no market activity for the same or similar instruments, the Company estimates the fair value using methods, models and assumptions that management believes market participants would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment which becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect risk inherent in a particular methodology, model or input employed.

The Company's financial assets and liabilities carried at estimated fair value have been classified, for disclosure purposes, based on a hierarchy defined by current accounting guidance. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The levels of the fair value hierarchy are as follows:

- Level 1 - Unadjusted quoted prices for identical assets or liabilities in an active market.
- Level 2 - Quoted prices for inactive markets or valuation techniques that require observable direct or indirect inputs for substantially the full term of the asset or liability.

Level 2 inputs include the following:
1. Quoted prices for similar assets or liabilities in active markets,
2. Observable inputs other than quoted market prices, and
3. Observable inputs derived principally from market data through correlation or other means.
- Level 3 - Prices or valuation techniques with unobservable inputs significant to the overall fair value estimate. These valuations use critical assumptions not readily available to market participants. Level 3 valuations are based on market standard valuation methodologies, including discounted cash flows, matrix pricing, or other similar techniques.

Assets and liabilities are valued as discussed below in part C.

(5) See parts (1) through (4) above.

B. Other Fair Value Disclosures - None

C. Fair Values for All Financial Instruments by Level 1, 2 and 3

| Type of Financial Instrument | Aggregate Fair Value | Admitted Assets | Level 1 | Level 2 | Level 3 | Net Asset Value (NAV) | Not Practicable (Carrying Value) |
|----------------------------------------------------------------------|----------------------|-------------------|---------------|-------------------|------------------|-----------------------|----------------------------------|
| Assets - Bonds | \$ 41,963,431,700 | \$ 38,723,164,492 | \$ 4,476,441 | \$ 38,744,844,389 | \$ 3,214,110,870 | \$ | \$ |
| Assets - Preferred stocks | 213,605,100 | 195,969,631 | | 115,750,319 | 97,854,780 | | |
| Assets - Common stocks unaffiliated | 147,388,812 | 147,388,812 | 27,371,340 | 94,048,358 | 25,969,114 | | |
| Assets - Mortgage loans - first liens | 7,682,858,809 | 7,477,523,067 | | | 7,682,858,809 | | |
| Assets - Mortgage loans - other than first liens | 1,264,371,952 | 1,278,106,136 | | | 1,264,371,952 | | |
| Assets - Policy loans | 152,556,066 | 152,556,066 | | 152,556,066 | | | |
| Assets - Cash and short-term investments | 3,457,165,284 | 3,459,887,673 | 3,366,114,919 | 90,055,365 | 995,000 | | |
| Assets - Derivative assets | 2,112,430,168 | 761,489,768 | 42,437,709 | 2,069,992,459 | | | |
| Assets - Derivative collateral assets | 7,560,000 | 7,560,000 | 7,560,000 | | | | |
| Assets - Other invested assets | 2,768,890,789 | 2,704,235,488 | | 527,664,953 | 833,534,733 | 1,407,691,103 | |
| Assets - Separate account: variable products | 29,957,081 | 29,957,081 | | 29,957,081 | | | |
| Assets - Separate account: group annuity | 11,247,745,277 | 10,487,032,255 | 93,274,806 | 9,641,551,232 | 1,462,764,368 | 50,154,871 | |
| Assets - Separate account: index-linked products | 259,224,281 | 257,835,479 | 148,753,141 | 106,210,446 | 4,260,695 | | |
| Liabilities - Deposit-type contracts | 901,735,482 | 843,621,427 | | 502,045,639 | 399,689,843 | | |
| Liabilities - Repurchase agreements | 911,431,554 | 911,431,554 | | 911,431,554 | | | |
| Liabilities - Derivative liabilities | 8,143,292 | 76,035,419 | 4,250,180 | (823,258) | 4,716,370 | | |
| Liabilities - Derivative and other collateral | 2,148,096,668 | 2,148,096,668 | 2,148,096,668 | | | | |
| Liabilities - Separate account: group annuity deposit-type contracts | 3,324,479 | 3,476,348 | | | 3,324,479 | | |
| Liabilities - Separate account: funding agreements | 2,191,747,845 | 2,009,928,869 | | 2,191,747,845 | | | |

Bonds and short-term investments – The Company obtains the fair value for most marketable, public bonds without an active market from several commercial pricing services. These are classified as Level 2 assets. The pricing services incorporate a variety of market observable information in their valuation techniques, including benchmark yields, broker-dealer quotes, credit quality, issuer spreads, bids, offers, and other reference data. If the Company cannot value a public bond with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3. The Company values privately placed bonds based on the credit quality and duration of comparable marketable securities, which may be securities of another issuer. In some instances, the Company uses a matrix-based pricing model. These models consider the current level of risk-free interest rates, corporate spreads, credit quality of the issuer, and cash flow characteristics of the security. Privately placed fixed maturity securities are classified as Level 2 or 3.

Preferred stocks and common stocks unaffiliated – The Company values equity securities, typically private equities or equity securities not traded on an exchange, using several commercial pricing services or an internal model. The securities priced by a commercial pricing service are classified as Level 2 and the securities priced by an internal model are classified as Level 3. In addition, unaffiliated common stocks include FHLB stock, which is carried at fair value, which is presumed to be par because it can only be redeemed by the bank and is classified as Level 2.

Notes to the Financial Statements

20. Fair Value Measurements (Continued)

Mortgage loans – The Company estimates mortgage loans on a monthly basis using discounted cash flow analysis and rates being offered for similar loans to borrowers with similar credit ratings. Loans with similar characteristics are aggregated for purposes of the calculations. The discounted cash flow model uses unobservable inputs, including estimates of discount rates and loan prepayments. Mortgage loans are classified as Level 3.

Policy loans – The fair value of policy loans classified as Level 2 is equal to the carrying value of the loans, which are collateralized by the cash surrender value of the associated insurance contracts.

Derivatives – Derivative contracts can be exchange traded or over-the-counter. Over-the-counter derivatives are valued using valuation models or an income approach using third-party broker valuations. Valuation models require a variety of inputs, including contractual terms, market prices, yield curves, measures of volatility, prepayment rates, and correlation of the inputs. The Company considers and incorporates counterparty credit risk in the valuation process through counterparty credit rating requirements and monitoring of overall exposure. The Company also evaluates and includes its own nonperformance risk in valuing derivatives. The majority of the Company's derivatives trade are in liquid markets; therefore, the Company can verify model inputs and model selection does not involve significant management judgment and are classified within Level 2. If the Company cannot verify model inputs and model selection does involve significant management judgment, the derivatives are classified as Level 3.

Other invested assets – Within other invested assets, partnerships are valued based on net asset value information provided by the general partner or related asset manager. These partnership interests usually include multiple underlying investments for which either observable market prices or other valuation methods are used to determine the fair value. These investments are reported in the Net Asset Value (NAV) column. Other than partnerships, other invested assets may include surplus notes and other investments with bond or stock characteristics and the Company attempts to value these using several commercial pricing services, which would be classified as Level 2 assets. If the Company cannot value with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3 assets.

Separate account assets (variable products) – Separate account assets classified as Level 2 are valued based on the fair value of the underlying funds. Fair values and changes in the fair values of the underlying funds accrue directly to the policy owners and are not included in the Company's revenues and expenses or surplus.

Separate account assets (group annuity) – Financial instruments within this separate account classified as Level 2 and 3 or included in the NAV column are valued using the same fair value assumptions and methods utilized in the general account.

Repurchase agreements - The carrying value of the repurchase agreements liability approximates fair value and is reported as level 2.

Deposit-type contracts (including separate account group annuity and funding agreements) – Deposit-type contracts classified as Level 3 include single premium immediate annuities (SPIA) and supplemental contracts. Fair value of SPIA and supplemental contracts are calculated by discounting best estimate cash flows based on mortality and market interest rate assumptions. Fair value of funding agreements are calculated by discounting future cash flows using market rates on the valuation date, and are classified as Level 2.

D. Not Practicable to Estimate Fair Value - None

E. Nature and Risk of Investments Reported at NAV

The Company invests in certain non-fixed income, alternative investments in the form of limited partnerships (investment funds) which are reported at NAV. Adjustments to the carrying amount reflect the Company's pro rata ownership percentage of the operating results as indicated by NAV in the investment fund financial statements. The NAV from the investment fund financial statements can be on a lag of up to three months when investee information is not received in a timely manner. These investments are listed in the NAV column of the fair value tables above as this is the primary method for reporting fair value for these investments.

As of September 30, 2020, the Company's general and separate accounts have \$700.7 million unfunded commitments to invest in these investment funds.

21. Other Items - No Significant Changes

22. Events Subsequent

Subsequent events have been considered through November 12, 2020 for the statutory statement dated September 30, 2020.

The Company did not write any accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act.

23. Reinsurance

Effective June 1, 2020, the Company recaptured a funds withheld agreement originally entered into with Athene Annuity Re Ltd. (AARe) on October 1, 2018. The agreement ceded 100% of all inforce and future funding agreements. The Company subsequently entered into a modified coinsurance agreement with AARe effective June 1, 2020 to cede a quota share of all inforce and certain future funding agreements. The reserves for this block were \$2,009.9 million as of September 30, 2020.

Effective June 1, 2020, the Company entered into a modified coinsurance agreement with AARe to cede a quota share of certain future funding agreements. There was no business ceded through this reinsurance agreement as of September 30, 2020.

A. Ceded Reinsurance Report - No Significant Changes

B. Uncollectible Reinsurance - None

C. Commutation of Ceded Reinsurance - None

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation - None

E. Reinsurance of Variable Annuity Contracts with an Affiliated Captive Reinsurer - None

F. Reinsurance Agreement with an Affiliated Captive Reinsurer - None

G. Ceding Entities That Utilize Captive Reinsurers to Assume Reserves Subject to the XXX/AXXX Captive Framework - None

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. Method Used to Estimate - None

B. Method Used to Record - None

Notes to the Financial Statements

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination (Continued)

- C. Amount and Percent of Net Retrospective Premiums - None
- D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act - None
- E. Risk-Sharing Provisions of the Affordable Care Act (ACA)
 - (1) Accident and health insurance premium subject to the Affordable Care Act risk-sharing provisions

Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions?
NO
 - (2) Impact of Risk-Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year - None
 - (3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance - None
 - (4) Roll-forward of risk corridors asset and liability balances by program benefit year - None
 - (5) ACA risk corridors receivable as of reporting date - None

25. Change in Incurred Losses and Loss Adjustment Expenses - None

26. Intercompany Pooling Arrangements - None

27. Structured Settlements - None

28. Health Care Receivables - None

29. Participating Policies - No Significant Changes

30. Premium Deficiency Reserves - None

31. Reserves for Life Contracts and Annuity Contracts - No Significant Changes

32. Analysis of Annuity Actuarial Reserves and Deposit Type Contract Liabilities by Withdrawal Characteristics - No Significant Changes

33. Analysis of Life Actuarial Reserves by Withdrawal Characteristics - No Significant Changes

34. Premiums and Annuity Considerations Deferred and Uncollected - No Significant Changes

35. Separate Accounts - No Significant Changes

36. Loss/Claim Adjustment Expenses - None